Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5441-5453

  Baritaki, Stavroula ^a   Katsman, Alina ^a   Chatterjee, Devasis ^b   Yeung, Kam C ^c   Spandidos, Demetrios A ^d   Bonavida, Benjamin ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d UNIVERSITY OF CRETE   (Greece)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BCL XL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YY1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL MEMBRANE DEPOLARIZATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MELANOMA CELL; METASTASIS; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FAMILY; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REPRESSOR GENE; TUMOR CELL; ADENOCARCINOMA; BIOSYNTHESIS; BONE TUMOR; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; MALE; MELANOMA; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR ESCAPE; UPREGULATION;

ADENOCARCINOMA; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; MALE; MELANOMA; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR ESCAPE; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; YY1 TRANSCRIPTION FACTOR;

EID: 38449120381     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5441     Document Type: Article

References (61)

1. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6: 715-727.
2. Medema, J. P., J. de Jong, L. T. Peltenburg, E. M. Verdegaal, A. Gorter, S. A. Bres, K. L. Franken, M. Hahne, J. P. Albar, C. J. Melief, and R. Offringa. 2001. Blockade of the granzyme B/perforin pathway through over-expression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 98: 11515-11520.
3. Ochsenbein, A. F. 2005. Immunological ignorance of solid tumors. Springer Semin. Immunopathol. 27: 19-35.
4. Chao, D. T., and S. J. Korsmeyer. 1998. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16: 395-419.
5. Tschopp, J., M. Irmler, and M. Thome. 1998. Inhibition of fas death signals by FLIPS. Curr. Opin. Immunol. 10: 552-558.
6. Deveraux, Q. L., and J. C. Reed. 1999. IAP family proteins: suppressors of apoptosis. Genes Dev. 13: 239-252.
7. Lee, H. H., H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng. 1999. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA 96: 9136-9141.
8. Gasparian, A. V., Y. J. Yao, D. Kowalczyk, L. A. Lyakh, A. Karseladze, T. J. Slaga, and I. V. Budunova. 2002. The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J. Cell Sci. 115: 141-151.
9. Pitti, R. M., S. A. Marsters, D. A. Lawrence, M. Roy, F. C. Kischkel, P. Dowd, A. Huang, C. J. Donahue, S. W. Sherwood, D. T. Baldwin, et al. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703.
10. Ashkenazi, A., and V. M. Dixit. 1999. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11: 255-260.
11. Soderstrom, T. S., M. Poukkula, T. H. Holmstrom, K. M. Heiskanen, and J. E. Eriksson. 2002. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169: 2851-2860.
12. Zhang, L., and B. Fang. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12: 228-237.
13. Shankar, S., and R. K. Srivastava. 2004. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat. 7: 139-156.
14. Baritaki, S., S. Huerta-Yepez, T. Sakai, D. A. Spandidos, and B. Bonavida. 2007. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: upregulation of DR5 and inhibition of YY1. Mol. Cancer Ther. 6: 1387-1399.
15. Shankar, S., X. Chen, and R. K. Srivastava. 2005. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62: 165-186.
16. Nagane, M., G. Pan, J. J. Weddle, V. M. Dixit, W. K. Cavenee, and H. J. Huang. 2000. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60: 847-853.
17. Sheikh, M. S., T. F. Burns, Y. Huang, G. S. Wu, S. Amundson, K. S. Brooks, A. J. Fornace, Jr., and W. S. el-Deiry. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res. 58: 1593-1598.
18. Sprick, M. R., M. A. Weigand, E. Rieser, C. T. Rauch, P. Juo, J. Blenis, P. H. Krammer, and H. Walczak. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
19. Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, and J. Tschopp. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2: 241-243.
20. Tran, S. E., T. H. Holmstrom, M. Ahonen, V. M. Kahari, and J. E. Eriksson. 2001. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276: 16484-16490.
21. Chen, X., K. Kandasamy, and R. K. Srivastava. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 63: 1059-1066.
22. Ravi, R., G. C. Bedi, L. W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E. J. Fuchs, and A. Bedi. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol. 3: 409-416.
23. Yoshida, T., A. Maeda, N. Tani, and T. Sakai. 2001. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507: 381-385.
24. Chatterjee, D., Y. Bai, Z. Wang, S. Beach, S. Mott, R. Roy, C. Braastad, Y. Sun, A. Mukhopadhyay, B. B. Aggarwal, et al. 2004. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J. Biol. Chem. 279: 17515-17523.
25. Simister, P. C., M. J. Banfield, and R. L. Brady. 2002. The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr. D Biol. Crystallogr. 58: 1077-1080.
26. Perry, A. C., L. Hall, A. E. Bell, and R. Jones. 1994. Sequence analysis of a mammalian phospholipid-binding protein from testis and epididymis and its distribution between spermatozoa and extracellular secretions. Biochem. J. 301: 235-242.
27. Mitake, S., K. Ojika, E. Katada, Y. Otsuka, N. Matsukawa, and O. Fujimori. 1995. Accumulation of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano bodies. Neuropathol. Appl. Neurobiol. 21: 35-40.
28. Odabaei, G., D. Chatterjee, A. R. Jazirehi, L. Goodglick, K. Yeung, and B. Bonavida. 2004. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv. Cancer Res. 91: 169-200.
29. Yeung, K. C., D. W. Rose, A. S. Dhillon, D. Yaros, M. Gustafsson, D. Chatterjee, B. McFerran, J. Wyche, W. Kolch, and J. M. Sedivy. 2001. Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell. Biol. 21: 7207-7217.
30. Corbit, K. C., N. Trakul, E. M. Eves, B. Diaz, M. Marshall, and M. R. Rosner. 2003. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 278: 13061-13068.
31. Yeung, K., T. Seitz, S. Li, P. Janosch, B. McFerran, C. Kaiser, F. Fee, K. D. Katsanakis, D. W. Rose, H. Mischak, et al. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177.
32. Kroslak, T., T. Koch, E. Kahl, and V. Hollt. 2001. Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J. Biol. Chem. 276: 39772-39778.
33. Park, S., M. L. Yeung, S. Beach, J. M. Shields, and K. C. Yeung. 2005. RKIP down-regulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24: 3535-3540.
34. Trakul, N., and M. R. Rosner. 2005. Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res. 15: 19-23.
35. Garban, H. J., and B. Bonavida. 2001. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J. Immunol. 167: 75-81.
36. Gordon, S., G. Akopyan, H. Garban, and B. Bonavida. 2006. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142.
37. Austen, M., B. Luscher, and J. M. Luscher-Firzlaff. 1997. Characterization of the transcriptional regulator YY1: the bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CPB)-binding protein. J. Biol. Chem. 272: 1709-1717.
38. Lee, J. S., K. M. Galvin, and Y. Shi. 1993. Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc. Natl. Acad. Sci. USA 90: 6145-6149.
39. L in Fas resistance and chemoresistance, respectively. J. Immunol. 175: 2174-2183.
40. Lee, H. H., H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng. 1999. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA 96: 9136-9141.
41. L expression. Oncogene 23: 4993-5003.
42. Nimmanapalli, R., C. L. Perkins, M. Orlando, E. O'Bryan, D. Nguyen, and K. N. Bhalla. 2001. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61: 759-763.
43. Chawla-Sarkar, M., J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden, and D. J. Lindner. 2003. Suppression of NF-κB survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J. Biol. Chem. 278: 39461-39469.
44. Palayoor, S. T., M. Y. Youmell, S. K. Calderwood, C. N. Coleman, and B. D. Price. 1999. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394.
45. Wang, H., E. Hertlein, N. Bakkar, H. Sun, S. Acharyya, J. Wang, M. Carathers, R. Davuluri, and D. C. Guttridge. 2007. NF-κB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27: 4374-4387.
46. Cory, G. O., and A. J. Ridley. 2002. Cell motility: braking WAVEs. Nature 418: 732-733.
47. Barnhart, B. C., J. C. Lee, E. C. Alappat, and M. E. Peter. 2003. The death effector domain protein family. Oncogene 22: 8634-8644.
48. L in human T-cells through nuclear factor-κB and c-AMP responsive element binding protein pathways. Virus Genes 22: 279-287.
49. L protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families. Histol. Histopathol. 16: 595-601.
50. Ng, C. P., and B. Bonavida. 2002. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by over-expression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 1: 1051-1058.
51. Fu, Z., P. C. Smith, L. Zhang, M. A. Rubin, R. L. Dunn, Z. Yao, and E. T. Keller. 2003. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95: 878-889.
52. Yang, X., D. R. Welch, K. K. Phillips, B. E. Weissman, and L. L. Wei. 1997. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 119: 149-155.
53. Keller, E. T., Z. Fu, K. Yeung, and M. Brennan. 2004. Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett. 207: 131-137.
54. Jazirehi, A. R. 2006. Regulation of chemo- and immuno-induced apoptosis by Raf-1 kinase inhibitor protein (RKIP): In Chemo-immunosensitization of Resistant Tumor Cells to Cell Death by Apoptosis, B. Bonavida, ed. Transworld Research Network, Kerala, India, p. 63-80.
55. Hamai, A., C. Richon, F. Meslin, F. Faure, A. Kauffmann, Y. Lecluse, A. Jalil, L. Larue, M. F. Avril, S. Chouaib, and M. Mehrpour. 2006. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene 25: 7618-7634.
56. L down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 64: 7117-7126.
57. Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. Pequignot, N. Casares, M. Terme, C. Flament, et al. 2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12: 214-219.
58. Merchant, M. S., F. Melchionda, M. Sinha, C. Khanna, L. Helman, and C. L. Mackall. 2007. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol. Immunother. 56: 1037-1046.
59. Pardoll, D. 2001. T cells and tumors. Nature 411: 1010-1012.
60. Eves, E. M., P. Shapiro, K. Naik, U. R. Klein, N. Trakul, and M. R. Rosner. 2006. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol. Cell 23: 561-574.
61. Rosner, M. R. 2007. MAP kinase meets mitosis: a role for Raf kinase inhibitory protein in spindle checkpoint regulation. Cell Div. 2: 1.